MBRX · Moleculin Biotech Inc
United States · RS rating 96 · As of 2026-11-03
| Price | 8.30 USD |
|---|---|
| 1-day change | -0.2% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 99 / 99 / 32 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 46 / 61 / 63 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +60.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +46.8% |
| Market cap (USD) | $13.6M |